Slide 1: Softer quarter due to lower sales in EMEA – Q1 Interim Report
Softer quarter due to Q1 CellaVision lower sales in EMEA Interim Report January–March 2026 Organic sales growth: Q1, 2026: -6.6% (+14.1) EBITDA margin: Q1, 2026: 24% (34) January 1st – Mars 31st, 2026 Net sales decreased by 14.6% (+14.6) to SEK 166 m (195). Sales decreased organically by 6.6% (+14.1
Slide 2: CEO's Comment
CEO’s Comment CellaVision started the year with an unforeseen inventory In EMEA, sales decreased by 32 percent to SEK 65 m (96), compared pick up in the second half of the year. CellaVision also submitted adjustment from our main distribution partner in EMEA. This to a strong first quarter of 2025.
Slide 3: Sales, Earnings and Investments
Sales, Earnings and Investments Net Sales and Currency Effects Operating Expenses Sales per quarter Net sales for the first quarter decreased to SEK 166 m (195), a Operating expenses for the first quarter increased by 7 percent to and rolling 12 months decrease of 15 percent compared to the correspo
Slide 4: Investments, Parent Company, Cash Flow
Investments Parent Company CellaVision continuously capitalizes expenses related to product Apart from the manufacturing of reagents, the group is in all development. During the quarter, capitalized development expenses material aspects represented by the operations in the parent amounted to SEK 12
Slide 5: Development in the Geographical Markets
Development in the Geographical Markets Americas: SEK 79 m (78) EMEA: SEK 65 m (96) APAC: SEK 22 m (21) Sales in the Americas increased by 2 percent, reaching SEK 79 m Sales in the EMEA region decreased by 32 percent to SEK 65 m (96), Sales in the APAC region increased by 4 percent to SEK 22 m (21),
Slide 6: Research and Development
Research and Development Our vision is to elevate healthcare through In parallel, the upgraded software version for the evolution of microscopy. By devoting CellaVision’s hematology instruments has been considerable resources to research and launched globally. The Digital Cell Morphology development
Slide 7: The Nomination Committee and Annual General Meeting in 2026
The Nomination Committee and Annual Declaration by the Board of General Meeting in 2026 Directors and President/CEO The Nomination Committee’s summarized proposal regarding Board The Board of Directors through the President/ Chief Executive Officer certify that the interim report before the Annual G
Slide 8: Income Statement in Summary and Consolidated Statement of Comprehensive Income, Group
Income Statement in Summary and Consolidated Statement of Comprehensive Income, Group Amounts in ‘ 000 SEK Note Jan-Mar 2026 Jan-Mar 2025 Jan-Dec 2025 Net sales 4 166,426 194,802 758,968 Cost of goods sold -52,434 -57,593 -239,091 Gross profit 113,992 137,209 519,877 Sales and marketing expenses -33
Slide 9: Per Share Data and Quarterly Earnings Trend
Per Share Data Per share data Jan-Mar 2026 Jan-Mar 2025 Jan-Dec 2025 Earnings per share, before and after dilution, SEK */ 0.94 1.74 6.42 Equity per share, SEK 38.33 35.16 37.21 Number of shares outstanding 23,851,547 23,851,547 23,851,547 Average number of shares outstanding 23,851,547 23,851,547 2
Slide 10: Balance Sheet in Summary, Group
Balance Sheet in Summary, Group Amounts in ' 000 SEK Note 03/31/2026 03/31/2025 12/31/2025 ASSETS Non-current assets Intangible assets 5 538,181 490,783 528,877 Tangible assets 6 122,345 112,307 122,374 Financial assets 7 2,550 2,460 2,544 Total non-current assets 663,076 605,550 653,794 Current ass
Slide 11: Consolidated Statement of Changes in Equity, Group
Consolidated Statement of Changes in Equity, Group Amounts in ' 000 SEK 03/31/2026 03/31/2025 12/31/2025 Balance at the beginning of the year 887,578 815,726 815,727 Dividend - - -59,629 Profit for the period 22,505 41,517 153,078 Other comprehensive income for the period 4,171 -18,710 -21,598 Closi
Slide 12: Cash Flow Statement in Summary, Group
Cash Flow Statement in Summary, Group Amounts in ‘ 000 SEK Jan-Mar 2026 Jan-Mar 2025 Jan-Dec 2025 Result before taxes 28,486 52,501 194,264 Adjustment for items not included in cash flow 16,450 14,266 40,837 Income tax paid -4,594 -8,919 -31,383 Cash flow from operating activities before changes in
Slide 13: Income Statement in Summary, Parent Company
Income Statement in Summary and Consolidated Statement of Comprehensive Income, Parent Company Amounts in ‘ 000 SEK Jan-Mar 2026 Jan-Mar 2025 Jan-Dec 2025 Net sales 122,515 148,899 583,505 Cost of goods sold -27,849 -31,741 -138,243 Gross profit 94,666 117,158 445,262 Sales and marketing expenses -2
Slide 14: Balance Sheet in Summary, Parent Company
Balance Sheet in Summary, Parent Company Amounts in ' 000 SEK 03/31/2026 03/31/2025 12/31/2025 ASSETS Non-current assets Intangible assets 23,205 26,196 23,953 Tangible assets 14,005 7,192 12,725 Deferred tax assets 532 755 532 Long term receivables from group companies 25,169 29,292 25,963 Financia
Slide 15: Notes
Notes NOTE 1. ACCOUNTING POLICIES NOTE 3. RISKS AND UNCERTAINTIES The Group applies IFRS Accounting Standards, as adopted by the EU. This interim report has been CellaVision is exposed to several risks, which may impact the Group’s development to a greater prepared in accordance with IAS 34 Interim
Slide 16: Notes, Cont'd
Notes, Cont’d NOTE 5. INTANGIBLE ASSETS NOTE 7. FINANCIAL ASSETS AND LIABILITIES The disclosed value of financial assets, trade receivables, other receivables, cash and bank, trade Amounts in ‘ 000 SEK 03/31/2026 03/31/2025 payables, and other short-term liabilities constitutes a reasonable approxim
Slide 17: Reconciliation Tables KPIs, Non-IFRS Measures
Reconciliation Tables KPIs, Non-IFRS Measures Equity-asset ratio Amounts in ' 000 SEK 03/31/2026 03/31/2025 The company presents certain financial measures in the interim Equity 914,254 838,533 report which are not defined according to IFRS. The financial Balance sheet total 1,134,781 1,043,869 metr
Slide 18: Questions Concerning the Report / Financial Calendar 2026
Questions Concerning Financial the Report Calendar 2026 Publication This information constitutes information that CellaVision AB (publ) is obliged to make Interim Report January-March public pursuant to the EU Market Abuse Regulation. The information was submitted April 24, 2026 for publication on A
Slide 19: This is CellaVision
This is Mission To advance laboratory workflow and diagnostic certainty Vision Elevating healthcare through the evolution of microscopy CellaVision through intelligent microscopy Our tools for automating cell classification with diagnostic We provide digital microscopy solutions to make laboratory w